BPX-201, a second generation autologous DeCIDe vaccine, is under evaluation in a Phase I multi-site clinical trial in combination with AP1903 for patients with mCRPC, that is now enrolling patients. A Phase I/II multi-site clinical trial evaluating the safety and feasibility of escalating doses of BPX-501, a CaspaCIDe-enabled T cell addback administered at the time of CD34-selected haploidentical HSCT for leukemia and lymphoma, is also now enrolling patients.
Previously, a single agent dose escalation Phase I trial of AP1903 in healthy volunteers was conducted by ARIAD Pharmaceuticals. BPX-101 was evaluated in a single site dose escalation Phase I/II clinical trial, in combination with AP1903, that enrolled 18 mCRPC patients and is now closed. CASPALLO, a Phase I trial of allodepleted T cells transduced with inducible caspase 9 suicide gene, is now closed.